<DOC>
	<DOCNO>NCT01365260</DOCNO>
	<brief_summary>The purpose study determine whether MM-II effective treatment osteoarthritis , direct comparison approve hyaluronic acid preparation .</brief_summary>
	<brief_title>Safety Efficacy Injectable Medical Device Treat Knee Osteoarthritis</brief_title>
	<detailed_description>Osteoarthritis ( OA ) common form joint disease , characterize articular cartilage degradation accompany periarticular bone response synovial membrane inflammation . Clinical manifestation OA knee include pain around joint , stiffness joint rest , crepitus motion limit joint . MM-II medical device design reduce wear low friction knee osteoarthritis patient create lubricate layer onto cartilage surface upon injection . The purpose study determine whether medical device MM-II effective treatment osteoarthritis , direct comparison approve hyaluronic acid preparation .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Symptomatic unilateral knee tibiofemoral OA Radiographic evidence knee OA KellgrenLawrence Grade II III one knees recent 3 month time XRay Knee pain within last 24 hour assessment 40mm VAS Pain day last month Knee pain equal 80mm 100mm VAS . Pain contra lateral knee ; 30mm 100 VAS . Concomitant inflammatory joint disease ( e.g . gout , rheumatoid arthritis , history Reiter 's syndrome , psoriatic arthritis ankylose spondylitis . Any condition may interfere measure pain target knee Concomitant meaningful synovial fluid effusion Post trauma OA Gross ligamentous instability knee</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>